Are You a Biotech Company Eyeing an IPO? Be Sure to Assess These 3 Areas First

Subscriber Content
Screenshot of the first page of Are You a Biotech Company Eyeing an IPO - Be Sure to Assess These 3 Areas First
Scott Glover, Protiviti Managing Director, San Francisco Life Sciences Practice Leader and Steve Hobbs, Protiviti Managing Director, Public Company Transformation

An IPO can help a biotech company raise capital quickly to support research and development (R&D), finance clinical trials and get products successfully to market. While it always helps to have the winds of a favorable market at your back, the main thing that really matters — and that investors will care about — is whether your biotech company is prepared to succeed in the future after it becomes a public company. This article outlines three specific areas that biotech companies should thoroughly assess when deciding whether to go public and points out other precautions to consider on the public company readiness journey.

Free Trial

Sign up for a free, no-obligation trial to start exploring our timesaving, valuable resources.